Sir, There is a growing body of evidence supporting the beneficial effects of idebenone in Leber's hereditary optic neuropathy (LHON, MIM 353500) , an inherited mitochondrial disease that causes rapid bilateral vision loss and lifelong legal blindness. Until recently, reports were limited to isolated case studies and small open-label case series (Mashima et al., 1992 (Mashima et al., , 2000 Cortelli et al., 1997; Carelli et al., 1998 Carelli et al., , 2001 Barnils et al., 2007) . However, in 2011, two articles published in Brain provided additional evidence for the therapeutic use of idebenone in LHON (Carelli et al., 2011; Klopstock et al., 2011) .
In the first complete randomized, placebo-controlled, doubleblind clinical trial in LHON [Rescue of Hereditary Optic Disease Outpatient Study (RHODOS), ClinicalTrials.gov identifier: NCT00747487], 85 unselected patients with LHON 514 years of age were randomized to receive 900 mg/day of idebenone or placebo in a 2:1 ratio for 24 weeks (Klopstock et al., 2011) . In the intent-to-treat population, visual acuity data were available for 82 patients harbouring one of the three primary mitochondrial DNA mutations (m.11778G4A, m.3460G4A and m.14484T4C) and experiencing first vision loss up to 5 years before study enrolment. All visual acuity end-points in the intent-to-treat population showed a consistent trend, with idebenone protecting patients from further vision loss, in contrast to the placebo group where visual acuity continued to deteriorate. Efficacy seen on visual acuity end-points was supported by independent measures including tests of colour contrast sensitivity. Following a pre-specified analysis by mutation, exclusion of patients with the m.14484T4C mutation, which is known for its high spontaneous recovery rate, resulted in a larger treatment effect in all visual acuity end-points. This finding was in agreement with the data from a retrospective analysis of 103 patients, published in the same issue of Brain (Carelli et al., 2011) . This study showed a significant difference in the incidence of visual recovery in idebenone-treated patients harbouring the m.11778G4A mitochondrial DNA mutation, known to cause $70% of LHON cases in Europe, and concluded that an early treatment start is recommended.
Vision loss in LHON is rapid, and in the majority of cases results in persistent lifelong visual impairment, typically rendering patients legally blind. Therefore, in light of the relatively short treatment duration of 24 weeks for RHODOS, we have now determined whether the observed treatment effects persisted after doi:10.1093/brain/aws279
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ß The Author (2013). Published by Oxford University Press on behalf of the Guarantors of Brain. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/ 3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. discontinuation of treatment. For this, we invited patients previously participating in RHODOS for reassessment of their visual acuity to a single visit observational follow-up study (RHODOS-OFU), which had ethical and institutional review board approval and was sponsored by Santhera Pharmaceuticals (ClinicalTrials.gov identifier: NCT01421381). According to the study protocol, the primary end-point was the change in best (logMAR) visual acuity at this study visit compared with baseline and Week 24 of RHODOS.
Sixty patients (70.6%) who participated in RHODOS were enrolled into this RHODOS-OFU study, of whom 58 patients provided visual acuity data in both studies and were included in the analysis. Of these, 39 patients had been randomized to idebenone in the course of RHODOS and 19 patients to placebo, in keeping with the 2:1 ratio of idebenone:placebo in the RHODOS study design. There were no significant differences in the demographics or molecular genetic characteristics of the RHODOS-OFU group compared with the original RHODOS cohort ( Table 1 ), indicating that the smaller subpopulation recruited to the RHODOS-OFU study was representative of the RHODOS study population. The mean AE SD time that had elapsed between Week 24 of RHODOS and the RHODOS-OFU study visit was 30.5 AE 4.9 months (median: 30.1 months). The time since onset of vision loss at baseline of RHODOS for this subpopulation was 23 AE 17 months (median: 18 months).
The change in best visual acuity from Week 24 of RHODOS to the follow-up visit did not correlate with the time elapsed (Spearman's correlation coefficient = À 0.045; P = 0.73) for the patients in this study. Therefore, the RHODOS-OFU visit was treated as a single categorical event in all statistical analyses, and for illustration purposes, the median time elapsed since the end of RHODOS (30 months = 131 weeks) is shown (Fig. 1) . The change in best visual acuity during the RHODOS treatment period up to Week 24 was very similar in the subpopulation of this study (n = 58) when compared with the outcome of this end-point in the intent-to-treat population of RHODOS (n = 82). Specifically, the mean difference in best visual acuity estimated by the mixed model of repeated measures for patients randomized to idebenone compared with patients receiving placebo was logMAR À 0.120 (six letters; P = 0.078; Fig. 2C in Klopstock et al., 2011) for the RHODOS intent-to-treat population, compared with logMAR À 0.175 (eight letters; P = 0.084; Fig. 1 , top panel and Table 2 ) for the patients in the RHODOS-OFU study. This indicates that the 58-patient subgroup is representative of the Week 24 outcome of the RHODOS intent-to-treat population, both in terms of demographics and visual acuity end-points.
Between Week 24 of RHODOS and the RHODOS-OFU visit 30 months later, best visual acuity followed parallel trajectories resulting in a non-significant trend towards improvement (logMAR À 0.08; four letters; Fig. 1, top panel) in each of the treatment groups, with no difference between groups (logMAR 0.002; P = 0.982; Table 2 ). Interestingly, this improvement in best visual acuity between the end of RHODOS and the RHODOS-OFU visit was confined primarily to patients with short disease history irrespective of treatment group (disease onset at RHODOS baseline 41 year, idebenone: logMAR À 0.155, placebo: À 0.198; disease onset 41 year: idebenone: À 0.038, placebo: À 0.054). The observed improvement in best visual acuity after discontinuation of the RHODOS treatment period may, at least in part, result from patients learning to use peripheral (extrafoveal) vision. The parallel trajectories after the end of RHODOS led to a mean difference of logMAR À 0.173 (eight letters improvement, P = 0.085) in best visual acuity between treatment groups for the entire period from baseline of RHODOS to the RHODOS-OFU visit, which is comparable with the difference observed at Week 24 (logMAR À 0.175, see previous text). Thus, the treatment effect observed after 24 weeks of idebenone was maintained long after therapy was terminated. The difference between treatment groups was larger in an analysis for patients carrying either the m.11778G4A or m.3460G4A mutation (i.e. excluding patients with the m.14484T4C mutation). Here, the mean difference between idebenone and placebo-treated patients between the baseline of RHODOS and the RHODOS-OFU visit was logMAR À 0.216 (10 letters, P = 0.0499). For the analysis of best recovery of visual acuity, the primary end-point of the RHODOS study, there was a logMAR À 0.147 (seven letters, P = 0.004) improvement between Week 24 of RHODOS and RHODOS-OFU in the idebenone group compared with a logMAR À 0.054 (two letters, P = 0.459) improvement in the placebo group. The mean difference in best recovery of visual acuity between treatment groups for the entire period from baseline of RHODOS to the RHODOS-OFU visit was logMAR À 0.158 (seven letters, P = 0.086).
In line with the previously described findings, when considering the change in visual acuity of all eyes (treated as independent), the idebenone group continued to improve between Week 24 of RHODOS and the RHODOS-OFU visit (mean change logMAR À 0.110, five letters; P = 0.005). However, the trajectory in visual acuity for patients in the placebo group did not change from Week 24 of RHODOS (Fig. 1, bottom panel) . This implies that in the placebo group, the improvement in best visual acuity might be offset by further deterioration of the worse affected eye. The resulting difference between treatment groups for the mean change in visual acuity of individual eyes from baseline of RHODOS to the RHODOS-OFU study visit was highly significant, logMAR À 0.228 (11 letters; P = 0.0011; Table 2 ), in favour of the idebenone group for patients carrying one of the three primary mitochondrial DNA mutations and logMAR À 0.283 (14 letters, P = 0.0002) for patients carrying either the m.11778G4A or m.3460G4A mutation.
Responder analysis in the RHODOS trial previously showed that for patients with 'off-chart' visual acuity in both eyes at baseline, none of the 13 patients in the placebo group but 7 out of 25 patients in the idebenone group had improved to reading at least a full line at Week 24 (P = 0.07) (Klopstock et al., 2011) . This was maintained for all five patients who participated in the RHODOS-OFU study, which again indicates the long-term persistence of the idebenone treatment effect. For the entire observation period, i.e. between baseline of RHODOS and the RHODOS-OFU visit, there were 50% (9 of 18) of patients with 'off-chart' visual acuity in the idebenone group and 25% (2 of 8) in the placebo group who improved to 'on-chart' visual acuity (P = 0.39). Counting eyes instead of patients for the same period, there were 18 of 44 (40.9%) eyes in the idebenone and 2 of 19 (10.5%) eyes in the placebo group that improved to 'on-chart' vision (P = 0.02).
We also performed a reviewer-requested alternative analysis of summary statistics. This included the change in average logMAR from baseline at Weeks 4, 12 and 24, the change from baseline to the follow-up visit described in this study and the change from Weeks 4, 12 and 24 to the follow-up visit. The results of this analysis were consistent with the mixed model of repeated measures analysis carried out in the original RHODOS study and the pre-specified analysis for the follow-on study.
In summary, the results from the single-visit RHODOS-OFU study demonstrated that the beneficial effect from 6 months of treatment with idebenone during RHODOS persisted despite discontinuation of therapy for a median time of 30 months. The underlying mechanism for this may be explained by the natural history and pathophysiology of LHON. Patients harbouring LHON mitochondrial DNA mutations usually remain asymptomatic until early adult life, when an ill-defined trigger precipitates acute loss of visual acuity. Reaching a nadir typically few months after disease onset, visual acuity rarely changes thereafter. Given what is known about the mode of action of idebenone (Haefeli et al., Letter to the Editor 2011), it is conceivable that the drug preserves or re-establishes retinal ganglion cell function during the acute phase, and thus protects from irreversible retinal ganglion cell loss. This is in keeping with the established hypothesis that, in the acute stage, the decrease in visual acuity in LHON is caused by respiratory chain dysfunction with viable, but inactive, retinal ganglion cells (Howell, 1998) . Consequently, the therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal, as suggested by the data of Carelli et al. (2011) . Mashima et al. (2000) and Carelli et al. (2011) both observed a mean time to recovery of $17 months while patients were continuously kept on treatment. The results of these studies indicate that prolonged treatment could result in a marked recovery of vision even in patients with established disease and severe visual acuity loss, an observation that was also supported by the recent anecdotal findings of Sabet-Peyman et al. (2012) , albeit in one patient. A treatment period 46 months might thus offer additional therapeutic benefit.
